A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma.
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 04 Oct 2011 Actual patient number 503 added as reported by ClinicalTrials.gov.